What are the responsibilities and job description for the Senior Director, Global Medical Affairs and Evidence Generation Asset Lead position at Argenx?
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.
We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients.
The Medical Affairs and Evidence Generation (MA&EG) Asset Lead provides expert medical insights to inform indication selection, target product profile development, clinical development plans, and pre-launch, and commercialization strategies working with global cross-functional team members from science, clinical development, medical affairs and evidence generation, and commercial. This strategic leader serves in a "player coach" capacity with responsibilities for the Integrated Evidence Generation Plans and other relevant MA&EG activities working with the broader MA&EG community members who support the asset. Additionally, as the molecule moves through its lifecycle this individual will also serve as a people manager with responsibilities for hiring MA&EG indication leads for the asset.
This individual will sit on the argenx Asset Strategy Team for the molecule and other related cross-functional teams to represent the totality of medical affairs activities, insights, and deliverables that will enable maximal patient benefit for the medicine. Additionally, this individual, who reports into the Global Head of MA&EG, will sit on the argenx MA&EG Leadership Team and be responsible for contributing to the evolution of MA&EG at argenx, helping to build a best-in-industry organization.
Specifically, this position is the MA&EG Strategy Lead for ARGX-119, a humanized agonist monoclonal antibody that specifically targets and activates muscle-specific kinase (MuSK) to promote the maturation and stabilization of the neuromuscular junction (NMJ). By activating MuSK, ARGX-119 aims to improve neuromuscular function, potentially reducing muscle weakness and fatigability in patients with neuromuscular diseases. ARGX-119 is being studied as a novel therapeutic approach for severe neuromuscular disorders such as congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy.
Roles and Responsibilities
- Serve as the MA&EG lead on the argenx-119 Asset Strategy Team to provide strategic guidance based on deep insights, with input from regional and country Medical Affairs teams (US, DE, JP, Developed Markets, Emerging and Partner Markets), to guide development and life cycle management of the argenx clinical asset, including the identification of new indications based on biology and mechanism of the disease that maximize patient outcomes and access
- Work closely with ARGX-119 Science, Clinical Development, Medical Affairs and Evidence Generation, and Commercial teams to execute all related lifecycle deliverables from development through commercialization including but not limited to providing input into development clinical trial protocols, study site selection, partnering with the clinical study team to troubleshoot study issues
- Develop and execute ambitious Integrated Evidence Generation Plans throughout the product lifecycle
- Lead the ARGX-119 MA&EG argenx Community and partner with colleagues to develop and execute medical strategies via scientific communications / publications, advisory boards, medical information, congress activities, medical field content development, and data generation activities; communicate with the Community regularly about the asset's development strategy and plans
- As the molecule progresses in its development, hire and manage a team of indication leads
- Co-create and help drive MA&EG strategies as a member of the MA&EG Leadership Team that align with and help accelerate achievement of argenx Vision 2030 with the expansion of our investment across indications, molecules, and patient impact
- Foster an inclusive and collaborative team environment that supports innovative solutions and strategies, works flexibly, and empowers people to do their best work
- Ensure all medical affairs activities maintain the highest standards, comply with applicable pharmaceutical regulation, as well as argenx policies and procedures
S KILLS AND COMPETENCIES
EDUCATION, EXPERIENCE AND QUALIFICATIONS
LI-Remote
At argenx, all applicants are welcomed in an inclusive environment. They will receive equal consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other applicable legally protected characteristics. argenx is proud to be an equal opportunity employer.
If you require reasonable accommodation in completing your application, interviewing, or otherwise participating in the candidate selection process please contact us at hr.us@argenx.com. Only inquiries related to an accommodation request will receive a response.
